Bio Rad Laboratories : -Rad Named One of the 2015 Top 100 Bay Area Innovators by Thomson Reuters
January 05, 2016 at 04:15 pm EST
Share
HERCULES, CA--(Marketwired - Jan 5, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced that it was named one of the "Thomson Reuters 2015 Top 100 Bay Area Innovators."
The award recognizes companies around the San Francisco Bay Area for their outstanding commitment to innovation, the protection of ideas, and the commercialization of inventions.
"We are honored to be recognized as one of the Top Bay Area Innovators for 2015 by Thomson Reuters," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "Over our more than 60-year history, innovation has been at the core of our business at Bio-Rad, helping us develop products that advance science and improve healthcare."
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,600 people worldwide and had revenues exceeding $2.1 billion in 2014. For more information, please visit www.bio-rad.com.
Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows:
- manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems;
- manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets;
- other (0.1%): in particular, manufacturing of analytical instruments.
At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore.
Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).